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Parasites in the genus Plasmodium cause disease throughout the tropic and subtropical regions of the world. P. falciparum, one
of the deadliest species of the parasite, relies on glycolysis for the generation of ATP while it inhabits the mammalian red blood
cell. The first step in glycolysis is catalyzed by hexokinase (HK). While the 55.3-kDa P. falciparum HK (PfHK) shares several bio-
chemical characteristics with mammalian HKs, including being inhibited by its products, it has limited amino acid identity
(26%) to the human HKs, suggesting that enzyme-specific therapeutics could be generated. To that end, interrogation of a se-
lected small-molecule library of HK inhibitors has identified a class of PfHK inhibitors, isobenzothiazolinones, some of which
have 50% inhibitory concentrations (IC50s) of <1 M. Inhibition was reversible by dilution but not by treatment with a reduc-
ing agent, suggesting that the basis for enzyme inactivation was not covalent association with the inhibitor. Lastly, six of these
compounds and the related molecule ebselen inhibited P. falciparum growth in vitro (50% effective concentration [EC50] of
>0.6 and <6.8 M). These findings suggest that the chemotypes identified here could represent leads for future development of
therapeutics against P. falciparum.
Malaria is a global health concern, infecting more than 200million people a year. While human malaria is commonly
caused by four members of the genus Plasmodium, P. falciparum
infection is responsible for the most mortality annually. In addi-
tion to disease, the burden of malaria has global economic conse-
quences, with an impact in developing nations that results from
reduced worker productivity and markedly increased disability-
adjusted life years (DALYs), a measure of disease burden as a
consequence of mortality and morbidity (World Health Organi-
zation [www.who.int]).
The parasite has a complex life cycle, with the intraerythrocytic
stage being primarily responsible for pathology. This stage of Plas-
modium lacks a complete tricarboxylic acid (TCA) cycle, and
knockout and inhibitor studies of mitochondrial proteins have
suggested that the mitochondrion is not a significant contributor
to cellular ATP levels (1, 2). Notably, glucose consumption was
found to be increased up to 100-fold in infected erythrocytes (3),
and lactate levels were 20 to 100 times higher than that from
uninfected cells (4, 5). These observations suggested that glycoly-
sis was playing a key metabolic role for the parasite during the
erythrocytic infection. Supporting this supposition, knockout
studies revealed that the hexose transporter responsible for im-
porting glucose was essential to the parasite, and inhibition of
glycolysis with glucose analogs rapidly depleted parasite ATP
(6, 7).
The first committed step in glycolysis, catalyzed by hexokinase
(HK), is the transfer of the -phosphoryl group from ATP to
glucose. This reaction yields glucose-6-phosphate (G6P), a me-
tabolite with multiple potential fates. First, it can be consumed in
glycolysis. Alternatively, if funneled into the pentose phosphate
pathway (PPP), the metabolite can serve in the generation of
NADPH, which is a key component in the P. falciparum antioxi-
dant defense and de novo nucleotide triphosphate biosynthesis
pathways (8).
The importance of glycolysis to the malaria parasite and the
observation that the single P. falciparum HK (PfHK) is predicted
to share limited (24%) identity with human glucokinases (HsGlk,
or HK IV) suggested that this enzyme could serve as a suitable
target for therapeutics (Fig. 1). Here, we describe the characteriza-
tion of recombinant PfHK. Further, we have interrogated a small-
molecule library of known HK inhibitors to identify potential lead
compounds that inhibit PfHK. Lastly, we have assessed the antip-
arasitic activity of these molecules against P. falciparum erythro-
cytic-stage parasites and have found that several are potent antip-
arasitic compounds.
MATERIALS AND METHODS
Chemicals and reagents. Glucose-6-phosphate dehydrogenase, -NAD
(NAD), ATP, and glucose were purchased from Sigma (St. Louis, MO).
Dimethyl sulfoxide (DMSO) was purchased from Fisher Scientific (Pitts-
burgh, PA), while phosphoenol pyruvate (PEP), 2-phenyl-1,2-benziso-
selenazol-3(2H)-one (ebselen [Eb]; PubChem substance identifier [SID]
856002) and glucosamine were obtained from VWR International (West
Chester, PA). The isobenzothiazolinones and benzamides used (see Table
2) were obtained from the University of Kansas Specialized Chemistry
Center (KUSCC).
Recombinant enzyme purification and assay conditions. The open
reading frame PF3D7_0624000 (PlasmoDB) for the P. falciparum hexoki-
nase (UniProt Q02155) was synthesized for codon optimization (Gene-
script, Piscataway, NJ), sequenced, and cloned into pQE30 (Qiagen, Va-
lencia, CA). Recombinant PfHK, an 55.3-kDa protein, was purified,
following a protocol developed for heterologous expression and purifica-
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tion of a HK from the African trypanosome. Briefly, a 10-ml bacterial
culture of Escherichia coli M15(pREP) harboring pQE30PfHK with PfHK
cloned in frame of a 6-His sequence (9) was used to inoculate a 1-liter
culture, which was grown to an optical density at 600 nm (OD600) of 1
and then induced for 24 h at room temperature (RT) with 500 M iso-
propyl -D-1-thiogalactopyranoside (IPTG) and purified as described
previously (9).
HK assays were performed in triplicate as described elsewhere, using a
coupled reaction to measure enzyme activity (9, 10). In short, the coupled
assay uses glucose-6-phosphate dehydrogenase (G6PDH) to convert glu-
cose-6-phosphate (G6P) generated by HK to 6-phosphogluconate with
coincident reduction of NADP to NADPH, which is monitored spectro-
photometrically at 340 nm. Kinetic analyses were performed using the
software program KaleidaGraph 4.1 (Synergy Software, Reading, PA).
Hexokinase inhibitor library. The collection of small molecules de-
scribed here as a “selected small-molecule library of HK inhibitors” was
originally developed, identified, and characterized as part of a high-
throughput screening (HTS) campaign targeting hexokinase 1 from the
African trypanosome, Trypanosoma brucei (TbHK1). This screen was
completed at the Pittsburgh Molecular Libraries Screening Center
(PMLSC) using a 220,233-compound library that was made available as
part of the NIH Molecular Libraries Roadmap Initiative. Analog develop-
ment of lead compound scaffolds, including the isobenzothiazolinones
and benzamidobenzoic acid derivatives used here, resulted from a chem-
ical probe development plan described in a probe report from the NIH
Molecular Libraries Program (11).
P. falciparum viability assay. Plasmodium falciparum 3D7 parasites
were grown in O red blood cells (RBCs) at 1% hematocrit cultured in
RPMI (plus L-glutamine, without NaHCO3) supplemented with 0.5%
Albumax, 0.37 mM hypoxanthine, 27 mM NaHCO3, 11 mM glucose, and
10 g/ml gentamicin under 5% CO2, 5% O2, and 90% N2 at 37°C. All
assays were performed in triplicate in a total volume of 100 l with
DMSO-only incubations as a negative control. Parasitemia was deter-
mined following 72 h of incubation by flow cytometry using acridine
orange staining (1.5 g/ml in phosphate-buffered saline [PBS], 5 min,
room temperature [RT], FACSCanto II flow cytometer [BD Biosystems,
Franklin Lakes, NJ]).
The dose-response curves for compounds that caused 50% growth
inhibition at 10 M were pursued in a 96-well plate format using an
asynchronous parasite culture. The starting parasitemia was 1%. Fifty
percent inhibitory concentrations (IC50s) were determined by scoring
parasite growth in three separate wells over a 2-fold dilution series starting
FIG 1 Alignments of PfHK, Trypanosoma brucei HK1 (TbHK1; Tb427.10.2010), and human glucokinase (HsGlk; ABS31137.1). Sequences were aligned using
CLUSTAL 0 (1.1.0) software. The “” symbol indicates completely conserved residues, while the colons (:) mark residues that share properties (0.5 in the
Gonnet PAM250 matrix). Periods (.) indicate residues that fall at 0.5 in the Gonnet PAM250 matrix, indicating weak similarity. The boxed residue is the
conserved catalytic base (Asp241 in PfHK).
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at 40 M for each compound. Percent inhibition was calculated by com-
parison to parasites grown in the DMSO controls from each plate. Chlo-
roquine was screened as a positive control starting at 1 M. Averages for
the triplicates were calculated, and dose-response curves were fitted and
IC50s determined using the software program Prism (GraphPad Soft-
ware).
RESULTS
While the importance of glycolysis to P. falciparum during mam-
malian infection has been established (3–5), the enzymes involved
in the process have not been subjected to in-depth characteriza-
tion. This is likely due to the difficulty of classically purifying the
parasite components from the complex milieu of the red blood
cell contents (which includes many related host activities). Addi-
tionally, the A-T-rich nature of the Plasmodium genome has his-
torically made production and analysis of recombinant enzymes
difficult.
Indeed, our initial forays into expression of PfHK in E. coli
were unsuccessful despite repeated efforts using a battery of ex-
pression vectors and bacterial cell lines. Expression was finally
achieved using a synthetic PfHK gene optimized with a codon bias
that reflected those codons employed by E. coli. The recombinant
enzyme, which was purified to 95% homogeneity (as deter-
mined by Coomassie staining of an SDS-PAGE gel), displayed
Michaelis-Menten kinetics when substrate levels were increased
(Fig. 2A) and had apparent Km values for glucose and ATP (0.62 
0.06 and 0.66  0.08 mM, respectively) similar to those from yeast
HK and T. brucei TbHK1 (Table 1) (9). The PfHK kcat value was
1.2 	 104 min
1, similar to that reported for a recently character-
ized T. brucei HK1 (2.9 	 104 min
1) (9). PfHK had an affinity for
MgCl2 (apparent Km  2.7  0.4 mM) similar to that of TbHK1
(apparent Km  0.92  0.21 mM). PfHK lacked detectable activity
when CaCl2 or MnCl2 was included in place of MgCl2 in the stan-
dard assay. The optimal pH for enzyme activity was found to be
about pH 7.4, with enzyme activity reduced 50% by a 1.2 pH
unit change in either the basic or acidic direction (Fig. 2B).
The enzyme lacked detectable activity when alternative phos-
phoryl donors, including UTP, GTP, CTP, TTP, ITP, and PPi,
were tested. Notably, ATP at concentrations greater than 3.5 mM
was inhibitory to the reaction (data not shown). Products also
inhibited the enzyme, with inclusion of ADP (10 mM) in the re-
action inhibiting the enzyme 94% (Fig. 3). PPi was also inhibi-
tory, while AMP only modestly (22%) inhibited PfHK at 10
mM. G6P, another product of PfHK, inhibited the enzyme 80%
at 10 mM.
Identification of small-molecule inhibitors of PfHK. The
completion of an HTS for inhibitors of T. brucei hexokinase 1
(TbHK1) yielded several scaffolds that have since been further
elaborated to resolve structure-activity relationships against that
enzyme (12). We have taken advantage of the reagents and assays
developed therein to interrogate this selected small-molecule li-
brary of HK inhibitors for PfHK inhibitors. These compounds
have been rigorously characterized. For example, they do not in-
hibit the coupled reporter enzyme, are typically poor inhibitors of
human glucokinase, have variable activity against TbHK1, and are
FIG 2 Effects of glucose concentration and pH on PfHK activity. (A) PfHK
(200 ng) activity in response to increasing glucose concentration. (B) The pH
profile of PfHK (200 ng) activity. Three different buffers with buffering capac-
ity in the range of pH tested were used for the assay: piperazine-N,N=-bis(2-
ethanesulfonic acid) (PIPES) (pH 6.2, 6.5, and 7.0), triethanolamine (pH 7.4),
and Tris (pH 8.0 and 8.8). Reactions were carried out in triplicate, and stan-
dard deviations are indicated.






rPfHK 1.2 	 104 0.62  0.06 0.66  0.08
rTbHK1b 2.9 	 104 0.09  0.02 0.28  0.1
a rPfHK and rTbHK1, recombinant PfHK and TbHK1.
b Data from reference 9.
FIG 3 Effects of phosphoryl-bearing compounds on PfHK activity. PfHK
(200 ng) activity was assessed in the presence of 5 mM ATP supplemented with
ADP, PPi, or AMP (all at 5 mM). Assays were performed in triplicate as de-
scribed in Materials and Methods, and standard deviations are indicated.
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minimally toxic to a number of mammalian cell lines (including
A549, IMR-90, HeLa, and MDA-MB-231 (12).
Of the 16 hits obtained from the HTS effort against TbHK1,
two groups were pursued as scaffolds for analog development
against TbHK1. Our interest in the first analog group, which was
based on five representative isobenzothiazolinones found in the
TbHK1 HTS, was particularly piqued because one analog, SID
92126115, had been previously identified in a screen performed by
GlaxoSmithKline of more than 2 million compounds for mole-
cules with anti-Plasmodium activity (http://www.ebi.ac.uk
/chemblntd) (13). SID 92126115, which inhibited parasite growth
97% at 2 M, was a potent PfHK inhibitor (IC50  0.16  0.04
M) (Table 2). Other isobenzothiazolinones lacking the halogen
substituents (SID 85747718 and SID 17387000) had slightly in-
creased IC50s, though substitution of the sulfur atom with a sele-
nium atom (to yield SID 856002, ebselen [Eb]) increased potency
of inhibition, a trend similar to that seen when Eb inhibition of
TbHK1 was compared to that seen with SID 17387000. Interest-
ingly, Eb and SID 17387000 inhibition was reversible by dilution
(Fig. 4 and data not shown), which is in contrast to the irreversible
inhibition observed with TbHK1 (M. T. Harris and J. C. Morris,
unpublished observation). The reducing reagent dithiothreitol
(DTT) was able to prevent but not reverse Eb inhibition of PfHK,
likely as a consequence of the preventative DTT binding directly to
Eb to block its interaction with the enzyme (14). Last, the presence
of the sulfur or selenium atom was important for inhibition of the
enzyme, since substitution with either a carbon or oxygen atom at
that position (SID 87225568 and 85752767, respectively) ablated
inhibition.
We also explored inhibition of PfHK with members of a second
scaffold identified in the TbHK1 HTS, based around the benzami-
dobenzoic acid identified in the screen (SID 93575727). Further
development of this class of compounds has yielded improved
inhibitors of TbHK1, including the probe ML205 (SID 99437306)
(Table 1) (11). However, against PfHK, representatives of this
class were either poor inhibitors (ML205 was 40% inhibitory at
10 M) or lacked detectable activity against the enzyme.
PfHK inhibitors are toxic to P. falciparum. Glycolysis is im-
portant to P. falciparum during the erythrocytic infection, sug-
gesting that inhibitors of the enzyme could be promising lead
compounds for therapeutic development. To explore this possi-
bility, we grew cultured Plasmodium parasites in the presence of
compound and monitored cell density after 72 h. Both the isoben-
zothiazolinones and benzamidobenzoic acid-based compounds
were tested in this assay, with 50% effective concentrations
(EC50s) determined for those that inhibited cell growth 50% at
10 M (Fig. 5 and Table 2). Compounds from the isobenzothia-
zolinone group included two of the most potent antimalarial
compounds, SID 92126115 and SID 85747718. While all of the
compounds that inhibited PfHK were toxic to parasites, one mol-
ecule (SID 85742034) was toxic to parasites while not inhibiting
PfHK. With the exception of SID 87225569, the antiparasitic com-
pounds had EC50s that were 4- to 680-fold higher than the PfHK
IC50s. This discrepancy could result from the inability of the mol-
ecules to reach their target as a consequence of limited RBC and/or
parasite cell permeability or trafficking. The identified PfHK in-
hibitors have minimal impact on human cell lines, with EC50s of
12.5 M (12), suggesting at least 20-fold-greater toxicity toward
parasites for the most potent compound (Table 2).
DISCUSSION
The intraerythrocytic malaria parasite requires extracellular glu-
cose for survival, largely due to the significant consumption of the
hexose as a consequence of ATP generation by glycolysis. Inhibi-
tors of this pathway have demonstrated potent antimalarial activ-
ity. These include small molecules that interfere with hexose
transport (15), as well as glucose analogs like 2-deoxyglucose
(6, 16).
PfHK, the first enzyme in glycolysis, has heretofore been con-
sidered an interesting potential target but has not been exploited
due to an inability to produce active recombinant protein for in
vitro characterization (17). Using an E. coli codon-optimized gene,
we have for the first time generated active PfHK. Characterization
of PfHK revealed it to share a number of features with other HKs,
including the finding that the reaction products G6P and ADP
were inhibitors of the enzyme, suggesting the Plasmodium protein
may be regulated via the feedback mechanism described for ver-
tebrate HKs (18). This observation was somewhat surprising
given that an HK from the related apicomplexan parasite Toxo-
plasma gondii (which is 44% identical to PfHK) is not sensitive to
substrate inhibition (19). PfHK is also kinetically similar to other
HKs, having glucose, ATP, and MgCl2 Km values similar to those
of HKs from other systems, including T. brucei and Homo sapiens.
The PfHK Km value for glucose was similar to that described by
Roth from activity associated with infected RBC lysates (620 M
and 431 M, respectively) (20). These values are 5-fold higher
than the Km reported from HK activity associated with uninfected
RBC lysates, suggesting that the host enzyme should outcompete
the parasite enzyme for glucose under limiting conditions. How-
ever, glucose transport in the intraerythrocytic parasite is highly
efficient, with the concentration of the substrate inside the para-
site rapidly reaching levels higher than that found in the external
medium (15).
The second PfHK substrate, ATP, is required for activity but
can also be an inhibitor of the enzyme. PfHK has a Km value for
ATP well below the intraerythrocytic ATP concentration (3
mM) and is inhibited at ATP levels approaching those found in
the host cytoplasm. While we anticipate that PfHK utilizes a pool
of ATP distinct from that found in the host cytoplasm, there could
be conditions under which the parasite has generated sufficient
ATP to satisfy its needs. To continue to synthesize ATP could be
damaging to the host cell, either directly as a consequence of
usurping host glucose or by depletion of host purines required for
ATP synthesis, since the parasite cannot synthesize purines and
must salvage them from the host. The finding that ATP is a regu-
lator of HK activity is not novel among HKs (21), though its role in
the malaria parasite remains unclear.
Taking advantage of a preexisting library of small molecules
designed around two scaffolds known to inhibit a trypanosome
HK, we searched for inhibitors of PfHK. The two enzymes share
limited sequence identity (28%) (Fig. 1), but nevertheless we
found that members of one of the two classes of analogues, the
isobenzothiazolinones, were more potent against PfHK than
against TbHK1 (Table 2). Additionally, the isobenzothiazolinone
analog Eb was extremely potent against PfHK (IC50  0.01 
0.00). Eb can promiscuously modify cysteine residues, and this
nonspecific interaction is known to be the mechanism of its inhi-
bition of some enzymes, such as human indoleamine 2,3-dioxy-
genase (22). However, site-directed mutagenesis of TbHK1 cys-
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teines, including the two conserved in PfHK (residues 273 and 398
in PfHK), did not alter TbHK1 sensitivity to Eb inhibition, indi-
cating that either cysteine residues are not involved in Eb inhibi-
tion or multiple cysteines must be bound in order for inhibition to
occur. Unlike the trypanosome enzyme, PfHK inhibition by Eb
and the isobenzothiazolinone SID 17387000 was reversible by di-
lution, suggesting that the inhibitors interact with the two en-
zymes differently.










92126115 0.16  0.04 3.8  0.40 0.62  0.06b
85747718 0.27  0.01 1.1  0.34 1.1  0.39
17387000 0.23  0.03 2.0  0.50 5.2  0.23
856002 (ebselen) 0.01  0.00 0.05  0.03 6.8  1.25
87225569 3.1  0.28 25 4.4  0.36
160644636 NDc ND 1.8  0.72
87325999 10 25 ND
85742034 10 25 5.1  0.82
85786735 10 25 ND
87225568 10 25 10
85752767 10 25 10
93575727 10 9.3  3.5 10
99437306 10 0.98  0.07 10
a Data from references 11 and 12.
b Identified in a GSK screen as inhibiting 3D7 P. falciparum growth 97% at 2 M (http://www.ebi.ac.uk/chemblntd [13]).
c ND, not determined.
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Previous research has demonstrated that Eb is toxic to P. fal-
ciparum, with EC50s similar to those found in our study (14 M
and 6.8 M, respectively) (23). Eb may have a polypharmacologi-
cal impact on the parasite, given the likely reactivity of the sele-
nium atom with cellular cysteines. However, it is nontoxic for
humans and is currently in phase III clinical trials for the treat-
ment of stroke survivors (Stroke Trials Registry Home Page as of
27 February 2013), suggesting that the consequences of off-target
effects in the human host may be tolerable.
The isobenzothiazolinone SID 92126115 was previously iden-
tified in a screen performed by GlaxoSmithKline of more than 2
million compounds for molecules with anti-Plasmodium activity,
inhibiting parasite growth 97% at 2 M (http://www.ebi.ac.uk
/chemblntd) (13). SID 92126115 was a potent PfHK inhibitor,
with an IC50 of 0.16  0.04 M. Isobenzothiazolinone inhibitors
of PfHK were also effective at inhibiting the growth of cultured
parasites, with EC50s below 10 M. The EC50s were higher that
IC50s found for PfHK, likely due to issues with cell permeability
and off-target interactions. With the exception of SID 85742034,
compounds that did not inhibit PfHK did not kill parasites.
In conclusion, several observations support the value of PfHK
as a therapeutic target. First, the single-copy gene product shares
limited (26%) identity with the human-equivalent enzyme. Sec-
ond, the enzyme is responsible for catalyzing the first reaction in
two critical pathways, glycolysis and the PPP, and is likely indis-
pensable for parasite viability. Last, inhibitors of the enzyme can
inhibit parasite proliferation, as demonstrated here. Together,
these findings suggest the value of further consideration of the
isobenzothiazolinone scaffold, as well as identification of addi-
tional new chemotypes, as a potential lead in therapeutic develop-
ment.
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